WATERTOWN, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic ...
Selecta Biosciences Inc. joined a licensing agreement with Takeda Pharmaceutical Co. Ltd. to develop AAV-driven gene therapies for two lysosomal storage disorders that could bring Watertown, ...
Next-generation IgG protease candidate Xork to be licensed for development with AT845, an investigational Astellas Gene Therapies' product, for the treatment of Pompe Disease Selecta to receive a $10M ...
Spark Therapeutics has gained exclusive worldwide rights to Selecta Biosciences’ Synthetic Vaccine Particles (SVP™) platform and exclusive options for up to four additional undisclosed genetic targets ...
(RTTNews) - Selecta Biosciences Inc. (SELB) expects topline data from the Phase 3 DISSOLVE clinical program investigating SEL-212 in chronic refractory gout in the first-quarter of 2023. The company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results